At CarboHyde, student training is not limited to cyclodextrins, laboratories and scientific discussions.
When students visit us, we also make sure they receive a proper introduction to Hungarian culture. And naturally, that includes a multi-stop journey through our world-famous—and not always particularly healthy—gastronomy.
So, we rented a few kayaks and headed out onto the Danube.
It was the perfect opportunity to cool down, enjoy the river and spend some time together outside the usual scientific environment.
Of course, no proper Hungarian summer experience would be complete without a stop in our world-famous—and not always particularly healthy—gastronomy.
After kayaking, it was time for:
LÁNGOS.
Deep-fried dough, usually topped with garlic, sour cream and plenty of cheese.
Healthy? Not exactly.
Well deserved after kayaking? Absolutely.
Hungarian? Very much so.
Cyclodextrin training, paddling on the Danube and a generous portion of lángos may sound like an unusual combination, but it made for a memorable CarboHyde day.
Because sometimes learning about cyclodextrins takes you beyond the laboratory.
And sometimes it ends with sour cream and cheese.
For our non-Hungarian readers: have you ever tried lángos? What toppings did you choose?
For a small and young company working in a highly specialized niche, reaching 6,000 followers on LinkedIn is a milestone we are truly proud of.
To us, this number means more than visibility. It reflects the growing interest in cyclodextrins and their expanding role across pharmaceuticals, biotechnology, formulation science, cosmetics, food, diagnostics, and other innovative industries.
At CarboHyde, we are committed to helping translate cyclodextrin science into real industrial value — from custom synthesis and analytical development to formulation support, R&D partnerships, innovation, and market access.
We are grateful to our partners, collaborators, customers, scientific community, and everyone who follows our journey. Your support confirms that even highly specialized science can reach a broad and engaged audience when it is connected to real-world challenges and opportunities.
Thank you for being part of the CarboHyde story.
Here’s to the next chapter — and to the future of cyclodextrin innovation!
LinkedIn version: “Great discussions about the future of healthcare, breakthrough innovations, and exciting partnership opportunities.”
Actual version: ☕ Coffee becoming a critical raw material 👣 Walking miles between meetings in the convention center 🤝 Explaining cyclodextrins for the 37th time today (not a made-up number) 🧬 Discussing everything from biologics and RNA therapies to personalized medicine 💡 Realizing that cyclodextrins are showing up in places nobody imagined 10 years ago 😅 Trying to remember whether this conversation was at Booth #1532, a networking reception, or while standing in line for coffee
What strikes me most at BIO this year is how much the conversation around cyclodextrins has evolved.
Not long ago, most discussions focused on solubility enhancement and formulation challenges. Today, we’re talking about cyclodextrins as active ingredients, enabling technologies for biologics, targeted delivery systems, and even personalized therapeutic approaches.
Trade shows are exhausting. The feet hurt, the voice gets tired, and the calendar becomes a blur of back-to-back meetings.
But every now and then, a conversation makes you stop and think: “Wait… could cyclodextrins actually play a role there too?”
And that’s usually when the most interesting ideas start.
To everyone exhibiting, networking, pitching, partnering, and surviving BIO this week: I see you. 😉
Great recognition for the GENEGUT project and our cyclodextrin science was received recently:
“Dear EU-funded innovator(s), We are writing to you as you are an official contact person for your organisation’s participation in the GENEGUT project funded by the European Commission under Horizon Europe.
We are delighted to inform you that one of the innovations developed in the project has been analysed by the European Commission’s Innovation Radar.
Details of this innovation, and how it was categorised by the analysis, are as follows:
Innovation Title: Scaling-up Environmentally-Friendly Processes for ad-hoc designed RNA-driven vehicles;
Market Maturity of the Innovation: Business Ready
Market Creation Potential of the innovation: Addresses needs of existing markets
In this analysis Innovation Radar also identified the following project partner(s) – including your organisation – in the project as a ‘Key Innovator’ in the development of this innovation: CarboHyde ZARTKORUEN MUKODO RESZVENYTARSASAG
In the near future we will publish the above information about this innovation on the European Commission’s Innovation Radar platform.”
So stay tuned, as soon you can read more about our RNA delivery platform on the EU’s portal too.
You may ask, where do cyclodextrin experts learn new tricks?
Of course, from other experts!
That is why we were extremely, grateful when Carmen Popescu from Roquette offered to give us a 2-day in person training. Even more so as Mohammad Qadir joined too.
So we gathered a small team of students and colleagues and are now bathing in cyclodextrin formulations.
In this study – differing from the GENEGUT concept – our CSO, Milo Malanga PhD, designed cyclodextrin polymers that can form nanoplexes with various oligonucleotides due to their cationic nature. The we compared them with a standard polymer in the field: polyethylenimine.
QABCDPS exhibited lower toxicity compared to PEI, effectively binding both siRNA and mRNA and delivering them into vesicles in the cytoplasm, but showing different internalization patterns.
Polyplexes formed with PEI showed stronger biological effect than those with QABCDPS, which can be attributed to the strength of interactions facilitated by the polymers.
“Dear EU-funded innovator(s), We are writing to you as you are an official contact person for your organization’s participation in the GENEGUT project funded by the European Commission under Horizon Europe.
We are delighted to inform you that one of the innovations developed in the project has been analyzed by the European Commission’s Innovation Radar.
Details of this innovation, and how it was categorized by the analysis, are as follows:
Innovation Title: Scaling-up Environmentally-Friendly Processes for ad-hoc designed RNA-driven vehicles;
Market Maturity of the Innovation: Business Ready
Market Creation Potential of the innovation: Addresses the needs of existing markets
In this analysis, Innovation Radar also identified the following project partner(s) – including your organization – in the project as a ‘Key Innovator’ in the development of this innovation: CarboHyde ZARTKORUEN MUKODO RESZVENYTARSASAG
In the near future, we will publish the above information about this innovation on the European Commission’s Innovation Radar platform.”
So stay tuned, as soon as you can read more about our RNA delivery platform on the EU’s portal too.
